According to current NICE guidelines, patients with gout who experience two or more attacks per year should receive urate-lowering therapy (ULT). When starting ULT, it is recommended to also prescribe colchicine cover for up to six months. If colchicine is not suitable, an alternative option is to consider NSAID cover.

While high-dose prednisolone can effectively treat acute gout, low-dose prednisolone is not recommended for gout prevention due to the negative effects of long-term corticosteroid use.

Although NSAIDs like naproxen or ibuprofen can be used to treat gout, this may not be the best option for someone with a history of hiatus hernia. Unlike xanthine oxidase inhibitors such as allopurinol or febuxostat, NSAIDs are not considered ULT and are therefore not suitable for gout prevention.

Gout is caused by chronic hyperuricaemia and is managed acutely with NSAIDs or colchicine. Urate-lowering therapy (ULT) is recommended for patients with >= 2 attacks in 12 months, tophi, renal disease, uric acid renal stones, or prophylaxis if on cytotoxics or diuretics. Allopurinol is first-line ULT, with a delayed start recommended until inflammation has settled. Lifestyle modifications include reducing alcohol intake, losing weight if obese, and avoiding high-purine foods. Other options for refractory cases include febuxostat, uricase, and pegloticase.

Key Findings from the PRACtICe Study on Prescribing Errors in General Practice

The PRACtICe study, commissioned by the GMC, provides valuable insights into the causes of drug prescribing errors in general practice. As an AKT candidate, it is highly recommended that you familiarize yourself with the study’s main conclusions, which can serve as a useful revision tool for the exam and help you avoid errors in your daily practice.

One of the key findings of the study is that 69% of monitoring errors were due to monitoring not being requested. This highlights the importance of ensuring that all necessary monitoring tests are requested and carried out for patients on medication. By being aware of such common causes of prescribing errors, you can take steps to minimize the risk of such errors occurring in your own practice.

Managing Hand, Foot and Mouth Disease

Hand, foot and mouth disease (HFMD) is a common viral illness that affects children. It is important to note that it is unrelated to foot and mouth disease in animals. HFMD is generally managed conservatively, with a focus on encouraging the child to have a good fluid intake. It is not a notifiable illness, so there is no need to complete a notification form.

If there are any signs of significant dehydration or neurological symptoms, such as persistent headaches or myoclonic jerks, referral to paediatrics should be considered. However, viral swabs are often not used in clinical practice for HFMD, as appropriate and cost-effective management is prioritized.

It is important for parents to be reassured that HFMD is a common and manageable illness. This guidance applies to the UK, but it may not apply to other countries.

Diagnostic Thresholds for Asthma Tests

FeNO tests, which measure nitric oxide levels in breath, are used to detect lung inflammation and asthma. The positive test threshold for adults is 40 ppb, while for children and young people it is 35 ppb or more. Obstructive spirometry, which measures FEV1/FVC ratio, has a positive test threshold of less than 70% for all age groups. Peak flow variability, which measures the difference between the highest and lowest peak flow readings, has a positive test threshold of over 20% for all age groups. While a peak flow variability of 50% is indicative of asthma, a threshold of 20% is used for diagnosis. It is important to note that some GP practices may not have access to FeNO testing equipment, which is a relatively new development in asthma diagnosis. Familiarizing oneself with these diagnostic thresholds is crucial in the context of NICE guidance, as the RCGP may test changes to guidance.

NICE Guidance on Assessing Pigmented Skin Lesions

NICE guidance on Suspected cancer: recognition and referral (NG12) recommends using the ‘7-point weighted checklist’ to evaluate pigmented skin lesions. This checklist includes major and minor features of lesions, with major features scoring 2 points each and minor features scoring 1 point each. Lesions scoring 3 or more points are considered suspicious and should be referred for further evaluation, even if the score is less than 3 and the clinician strongly suspects cancer.

For example, if a patient has a pigmented skin lesion that has changed in size and has an irregular shape, they would score 2 points for each major feature. Additionally, if the lesion has a diameter of 8 mm or more, it would score a single point for a minor feature. Therefore, the overall score for this lesion would be 5, indicating that it is suspicious and requires further evaluation.

It is important for clinicians to use this checklist when assessing pigmented skin lesions to ensure that potential cases of skin cancer are not missed.

Understanding RIDDOR and Reportable Accidents

For the purposes of RIDDOR, an accident is defined as a separate, identifiable, unintended incident that causes physical injury. This includes acts of non-consensual violence to people at work. However, not all accidents need to be reported. A RIDDOR report is only required when the accident is work-related and results in an injury of a type which is reportable as listed under HSE’s list of ‘Types of reportable injuries’.

In this case, exercise-induced asthma, myopia, and type 1 diabetes are not work-related. Fractures to fingers, thumbs, and toes are excluded from reporting, but other fractures are reportable. Occupational diseases such as occupational asthma or dermatitis are also reportable.

It is important to understand the criteria for reportable accidents under RIDDOR to ensure that incidents are reported appropriately.

Patients with RA who are taking etanercept are at a higher risk of developing infections, including chest infections and sepsis. If an infection does occur, it is important to discontinue the use of etanercept until the infection has been cleared. Additionally, biologic therapy can increase the risk of TB or reactivation of latent TB, and patients on this type of therapy require regular blood monitoring. This includes a full blood count, urea and electrolytes (with creatinine), and liver function tests initially, followed by monitoring every 6 months once stable, unless there is a clinical need for more frequent monitoring.

Rheumatoid arthritis (RA) management has been transformed by the introduction of disease-modifying therapies in recent years. Patients with joint inflammation should begin a combination of disease-modifying drugs (DMARD) as soon as possible. Other important treatment options include analgesia, physiotherapy, and surgery.

In 2018, NICE updated their guidelines for RA management, recommending DMARD monotherapy with or without a short course of bridging prednisolone as the initial step. Previously, dual DMARD therapy was advocated. To monitor response to treatment, NICE suggests using a combination of CRP and disease activity (using a composite score such as DAS28).

Flares of RA are often managed with corticosteroids, either orally or intramuscularly. Methotrexate is the most commonly used DMARD, but monitoring of FBC & LFTs is essential due to the risk of myelosuppression and liver cirrhosis. Other important side-effects include pneumonitis. Other DMARDs include sulfasalazine, leflunomide, and hydroxychloroquine.

TNF-inhibitors are indicated for patients who have had an inadequate response to at least two DMARDs, including methotrexate. Etanercept is a recombinant human protein that acts as a decoy receptor for TNF-α and is administered subcutaneously. Infliximab is a monoclonal antibody that binds to TNF-α and prevents it from binding with TNF receptors, and is administered intravenously. Adalimumab is also a monoclonal antibody, administered subcutaneously. Risks associated with TNF-inhibitors include reactivation of tuberculosis and demyelination.

Rituximab is an anti-CD20 monoclonal antibody that results in B-cell depletion. Two 1g intravenous infusions are given two weeks apart, but infusion reactions are common. Abatacept is a fusion protein that modulates a key signal required for activation of T lymphocytes, leading to decreased T-cell proliferation and cytokine production. It is given as an infusion but is not currently recommended by NICE.

Certain medications and substances can cause an increase in blood pressure, known as drug-induced hypertension. Non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 selective agents cause sodium and water retention, leading to elevated blood pressure. Sympathomimetic amines, such as amphetamines and pseudoephedrine, can also have this effect. Corticosteroids, particularly those with strong mineralocorticoid effects, can cause fluid retention and hypertension. Oral contraceptives may slightly raise blood pressure in some women. Venlafaxine increases levels of norepinephrine, contributing to hypertension. Cyclosporine and tacrolimus, used in transplant and autoimmune patients, can also have a significant effect on blood pressure. Caffeine and certain dietary supplements, such as ginseng, natural liquorice, and yohimbine, can also cause drug-induced hypertension.

Understanding Sydenham’s Chorea: A Common Cause of Acute Chorea Worldwide

Sydenham’s chorea, also known as St Vitus’ dance, is a neurological manifestation of rheumatic fever and remains the most common cause of acute chorea worldwide. While it was commonly seen in the 1930s, it occurs less frequently in the UK today. This condition can occur with or without symptoms of rheumatic fever and is usually self-limiting. Improvement occurs over about two weeks, but total recovery can take up to nine months, and may recur in some patients.

In this scenario, the short time course of the chorea and the girl’s age are useful diagnostically. It is important to note that psychological changes may precede or accompany the choreiform movements, as demonstrated by the girl’s emotional lability.

It is important to consider other potential causes of chorea, such as cerebral tumour, cerebrovascular accident, Guillain–Barré syndrome, and Huntington’s chorea. However, in this case, these conditions are unlikely as they do not fit with the girl’s symptoms and age.

Prescribing Considerations for Pregnant Patients

When it comes to prescribing medication for pregnant patients, it is important to exercise caution as very few drugs are known to be completely safe during pregnancy. Some countries have developed a grading system to help guide healthcare professionals in their decision-making process. It is important to note that the following drugs are known to be harmful and should be avoided: tetracyclines, aminoglycosides, sulphonamides and trimethoprim, quinolones, ACE inhibitors, angiotensin II receptor antagonists, statins, warfarin, sulfonylureas, retinoids (including topical), and cytotoxic agents.

In addition, the majority of antiepileptics, including valproate, carbamazepine, and phenytoin, are potentially harmful. However, the decision to stop such treatments can be difficult as uncontrolled epilepsy poses its own risks. It is important for healthcare professionals to carefully weigh the potential risks and benefits of any medication before prescribing it to a pregnant patient.

To avoid the risk of birth defects, trimethoprim should not be used during the first trimester of pregnancy. When a urinary tract infection is suspected in women, it is recommended to start treatment before waiting for culture results. However, a urine culture and sensitivity test should be done before starting antibiotics and again seven days after completing treatment to ensure it was effective. Local guidelines for prescribing antibiotics should be followed, and cefalexin is a safe alternative to trimethoprim. The current recommendation is to take antibiotics for seven days.

Understanding Trimethoprim: Mechanism of Action, Adverse Effects, and Use in Pregnancy

Trimethoprim is an antibiotic that is commonly used to treat urinary tract infections. Its mechanism of action involves interfering with DNA synthesis by inhibiting dihydrofolate reductase. This may cause an interaction with methotrexate, which also inhibits dihydrofolate reductase. However, the use of trimethoprim may also lead to adverse effects such as myelosuppression and a transient rise in creatinine. The drug competitively inhibits the tubular secretion of creatinine, resulting in a temporary increase that reverses upon stopping the medication. Additionally, trimethoprim blocks the ENaC channel in the distal nephron, causing a hyperkalaemic distal RTA (type 4). It also inhibits creatinine secretion, which often leads to an increase in creatinine by around 40 points, but not necessarily causing AKI.

When it comes to the use of trimethoprim in pregnancy, caution is advised. The British National Formulary (BNF) warns of a teratogenic risk in the first trimester due to its folate antagonist properties. Manufacturers advise avoiding the use of trimethoprim during pregnancy. It is important to consult with a healthcare provider before taking any medication, especially during pregnancy, to ensure the safety of both the mother and the developing fetus.

It is not appropriate to ignore the situation when you have witnessed the patient driving. Instead, you should inform the patient about the DVLA regulations and your obligation to report them if they refuse to stop driving. Reporting the patient to the DVLA immediately may harm your relationship with them, and it is better to give them a chance to rectify the situation themselves. It is always best to be transparent with patients about your actions.

Confiscating the patient’s keys is not a practical solution and may lead to conflict.

It is important to note that the new ‘6 month rule’ only applies to patients who have experienced their first seizure and have undergone an investigation, rather than those with pre-existing epilepsy.

Understanding Different Types of Dementia: Differential Diagnosis for Memory Impairment

Memory impairment is a common symptom in older adults, and it can be caused by various conditions, including dementia. Dementia affects approximately 5% of people over 65 and 20% of individuals over 80. Alzheimer’s disease is the most common cause of dementia, accounting for around 60% of cases. However, other types of dementia should also be considered in the differential diagnosis.

Depression is an important differential diagnosis in an older person presenting with memory impairment. Apathy and disconnection with activities that the patient previously enjoyed are common symptoms of depression. Mild cognitive impairment (MCI) is another condition that can cause memory impairment. However, MCI is characterized by memory impairment with preservation of other cognitive domains and intact activities of daily living.

Lewy-body dementia is a type of dementia that accounts for approximately 20% of cases. It usually presents with parkinsonism, fluctuating cognitive impairment, and visual hallucinations. Vascular dementia (vascular cognitive impairment) is another type of dementia caused by cerebrovascular disease. It is a progressive disease where deteriorations may be sudden or gradual but tend to progress in a stepwise manner.

In this case, the patient’s mini-mental state examination result supports the diagnosis of Alzheimer’s disease. The patient (or their relatives) commonly complains of difficulty with common activities of daily living and short-term memory loss. It is important to consider all possible causes of memory impairment to provide appropriate treatment and support for patients and their families.

If a patient with T2DM cannot take metformin due to contraindications and has a risk of CVD, established CVD, or chronic heart failure, the recommended initial therapy is SGLT-2 monotherapy.

NICE has updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022 to reflect advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors. For the average patient taking metformin for T2DM, lifestyle changes and titrating up metformin to aim for a HbA1c of 48 mmol/mol (6.5%) is recommended. A second drug should only be added if the HbA1c rises to 58 mmol/mol (7.5%). Dietary advice includes encouraging high fiber, low glycemic index sources of carbohydrates, controlling intake of saturated fats and trans fatty acids, and initial target weight loss of 5-10% in overweight individuals.

Individual HbA1c targets should be agreed upon with patients to encourage motivation, and HbA1c should be checked every 3-6 months until stable, then 6 monthly. Targets should be relaxed on a case-by-case basis, with particular consideration for older or frail adults with type 2 diabetes. Metformin remains the first-line drug of choice, and SGLT-2 inhibitors should be given in addition to metformin if the patient has a high risk of developing cardiovascular disease (CVD), established CVD, or chronic heart failure. If metformin is contraindicated, SGLT-2 monotherapy or a DPP-4 inhibitor, pioglitazone, or sulfonylurea may be used.

Further drug therapy options depend on individual clinical circumstances and patient preference. Dual therapy options include adding a DPP-4 inhibitor, pioglitazone, sulfonylurea, or SGLT-2 inhibitor (if NICE criteria are met). If a patient doesn’t achieve control on dual therapy, triple therapy options include adding a sulfonylurea or GLP-1 mimetic. GLP-1 mimetics should only be added to insulin under specialist care. Blood pressure targets are the same as for patients without type 2 diabetes, and ACE inhibitors or ARBs are first-line for hypertension. Antiplatelets should not be offered unless a patient has existing cardiovascular disease, and only patients with a 10-year cardiovascular risk > 10% should be offered a statin.

The Blacklist and Selected List in the Drug Tariff

The Drug Tariff has two important lists that determine what products can be prescribed on an NHS prescription. Part XVIIIA of the Drug Tariff, also known as ‘the blacklist’, contains a list of food, drug, toiletry, and cosmetic products that cannot be prescribed on the NHS. However, medical devices can be prescribed if they are listed in Part IX of the Drug Tariff.

If a proprietary product is listed in ‘the blacklist’, it cannot be dispensed on the NHS, unless the prescription is issued using a generic name that is not included in the blacklist. For instance, Propecia and Regaine, which are used for male-pattern alopecia, are blacklisted products. However, Calpol, which contains paracetamol suspension, can be prescribed despite being a blacklisted product.

On the other hand, Part XVIIIB of the Drug Tariff, also known as the Selected List, contains items that can only be prescribed for specific patient groups and purposes listed in the Drug Tariff. Prescribers must endorse prescriptions for these products with ‘SLS’. It is important to note that sildenafil was removed from the Selected List in 2014 and can now be prescribed freely.

In summary, prescribers must be aware of the products listed in the Drug Tariff’s blacklist and Selected List to ensure that they prescribe the appropriate products for their patients.

Medical Conditions and Their Associated Risks

Polycystic kidney disease is a condition that can lead to renal failure and is strongly linked to berry aneurysm. However, Autosomal Dominant Polycystic Kidney Disease (ADPKD) doesn’t increase the risk of renal carcinoma, nor does the rarer recessive type. On the other hand, patients on dialysis who develop cystic kidneys have a higher incidence of RCC, and Von-Hippel-Lindau disease also carries an increased risk.

Neurofibromatosis may be associated with phaeochromocytoma, while polycystic ovary disease carries a higher risk of endometrial cancer. However, psoriasis doesn’t predispose to skin cancer, and De Quervain’s thyroiditis doesn’t lead to malignancy. Finally, Gilbert’s disease is a benign familial abnormality of bilirubin metabolism.

Folic Acid Requirements for Women During Pregnancy

Most women are advised to take 400 mcg of folic acid daily from before conception until week 12 of pregnancy. However, there are exceptions to this rule. Women who are at a higher risk of neural tube defects, such as those with a history of bearing children with NTDs, or women with diabetes or taking anticonvulsants, should take a higher dose of 5 mg daily from before conception until week 12 of pregnancy.

Another group of women who require a higher dose of folic acid are those with sickle cell disease. They need to take 5 mg of folic acid daily throughout pregnancy, and even when not pregnant, they’ll usually be taking folic acid 5 mg every 1 to 7 days, depending on the severity of their disease. It’s important for women to consult with their healthcare provider to determine the appropriate dose of folic acid for their individual needs during pregnancy.

Distinguishing Different Skin Lesions: Dermatofibroma, Malignant Melanoma, Seborrhoeic Keratosis, Cutaneous Metastasis, and Actinic Keratosis

When it comes to skin lesions, it’s important to distinguish between different types to determine the appropriate treatment. One such lesion is a dermatofibroma, which is a benign growth that often appears on the limbs of women. A key feature of a dermatofibroma is the dimpling that occurs when the skin is pinched, due to the fibrous tissue underneath.

On the other hand, malignant melanoma is less likely to be the cause of a skin lesion if it has regular pigmentation, hasn’t changed in several months, and has dimpling – all features of a dermatofibroma. Seborrhoeic keratosis, another type of skin lesion, has a rough, stuck-on appearance that doesn’t match the description of a dermatofibroma.

A cutaneous metastasis, which is a skin lesion that results from cancer spreading from another part of the body, typically presents as a rapidly growing nodule. This is different from a dermatofibroma, which is relatively static. Similarly, an actinic keratosis, a flat lesion with a fine scale, is unlikely to be the diagnosis for a nodular lesion like a dermatofibroma.

In summary, understanding the characteristics of different skin lesions can help in accurately identifying and treating them.

Prostate Cancer in England and Wales

Approximately 10,000 men die of prostate cancer each year in England and Wales, making it the second leading cause of cancer deaths in men after lung cancer. The lifetime risk of a prostate cancer diagnosis in the UK is 1 in 14 men. However, one of the difficulties with investigating and diagnosing prostate cancer in older men is that as we age, most men have detectable prostate cancer. But, three-quarters of them will grow older and die of something else, and the prostate cancer itself will not impact their life expectancy.

The five-year survival rate from prostate cancer in the UK is 81%, which is relatively high compared to other types of cancer. However, early detection and treatment are crucial for improving survival rates. Therefore, it is important for men to be aware of the symptoms of prostate cancer and to undergo regular screenings, especially if they are at higher risk due to factors such as age, family history, or ethnicity. By detecting prostate cancer early, men can receive timely treatment and improve their chances of survival.

Investigating Bowel Symptoms in Patients with Irritable Bowel Syndrome

A patient with a history of irritable bowel syndrome (IBS) presenting with acute bowel symptoms is a common scenario. However, if their symptoms have undergone a marked change and become more persistent than usual, it is important to consider the possibility of colorectal cancer. In this context, an abdominal X-ray or ultrasound is not appropriate, and testing for inflammatory markers such as ESR doesn’t provide specific information that would aid referral. Tumour marker testing is also not an appropriate primary care investigation.

According to NICE guidelines, quantitative faecal immunochemical tests should be offered to assess for colorectal cancer in adults without rectal bleeding who are aged 50 and over with unexplained abdominal pain or weight loss, or aged under 60 with changes in their bowel habit or iron-deficiency anaemia. It is important to follow these guidelines to ensure appropriate investigation and referral for patients with IBS and changing bowel symptoms.